novo-venture-companies-25.html
Novo Annual Report 2015
26 / 72
2015
was another great liquidity year for novo?s private
portfolio
companies
. during the year, we saw one company acquired by novartis and four private
portfolio
companies
become publicly traded
companies
on nasdaq in the us.
2015
public crop ? adaptimmune (adap) ? colucid pharmaceuticals (clcd) ? htg molecular diagnostics (htgm) ? tobira therapeutics (tbra) a busy public year early may
2015
was a particular busy time for us. in just three days, four of novo?s
portfolio
companies
became publicly traded
companies
. tobira therapeutics merged with regado biosciences on 5 may; colucid pharmaceuticals and htg molecular completed their initial offerings on 6 may; and adaptimmune went public on nasdaq on 7 may. m&as and ipos in
2015
switzerland france finland denmark uk usa number of successful exits per country invested 1 1 1 3 4 29 switzerland france finland canada sweden uk denmark usa number of all exits per country 1 1 1 1 1 7 16 45
2015
was another great liquidity year for novo?s private
portfolio
companies
. spinifex was sold to novartis for usd 200 million and four private
portfolio
companies
went public on nasdaq. novo a/s 26 novo ventures
pain-neuropathic-spinifex-27.html
